930272-60-9

Usage

Uses

Used in Organic Synthesis:
(5-MethylpyriMidin-2-yl)MethanaMine is used as a building block in organic synthesis for the creation of new molecules with potential applications across various industries. Its reactivity allows for the formation of diverse chemical structures, facilitating the development of innovative compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (5-MethylpyriMidin-2-yl)MethanaMine is utilized as a key component in the design and synthesis of pharmaceutical drugs. Its incorporation into drug molecules can potentially enhance their biological activity, leading to the discovery of new therapeutic agents.
Used in Pharmaceutical Drug Development:
(5-MethylpyriMidin-2-yl)MethanaMine is employed as a precursor in the development of pharmaceutical drugs, where its unique structure and properties can contribute to the creation of novel therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Development:
(5-MethylpyriMidin-2-yl)MethanaMine also finds application in the agrochemical industry, where it is used in the synthesis of new agrochemicals with potential pesticidal or herbicidal properties, aiming to increase crop yields and protect plants from harmful organisms.

Upstream product

• 930272-56-3 2-(tert-butoxycarbonyl-aminomethyl)-5-methylpyrimidine 
• 38275-54-6 5-methylpyrimidine-2-carbonitrile 
• 38275-57-9 5-bromopyrimidine-2-carbonitrile 

Downstream Products

• 930272-56-3 2-(tert-butoxycarbonyl-aminomethyl)-5-methylpyrimidine 

Relevant academic research and scientific papers

Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds

Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.

High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity

We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (±)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.